Progress, Potential, and Possibilities Podcast / Show Dr. Rolland Carlson, PhD - CEO, Immunexpress, Inc. - Improving Outcomes For Patients With Sepsis
Dr. Rolland Carlson, PhD, is Chief Executive Officer of Immunexpress, Inc. ( https://immunexpress.com/company-overview/ ), a Seattle-based molecular diagnostic company committed to improving outcomes for patients suspected of having sepsis. Immunexpress' FDA cleared SeptiCyte™ technology rapidly quantifies, directly from whole blood, specific molecular markers from the patient's own immune system – the 'host response'. SeptiCyte™ LAB, is the first of its kind in using the host immune system to differentiate systemic inflammatory response syndrome (SIRS) and sepsis. Detecting the host's response to infection has the potential to differentiate infection earlier, faster and more accurately than finding the invading pathogen because it is independent of whether or not the pathogen is present in the sample. Dr. Carlson brings over 25 years of global commercial, business development, new product development and general management experience in biotechnology. Dr. Carlson most recently served as President and CEO of WaferGen Biosystems, genomic analysis company; prior to that he was President and CEO of Asuragen, a privately-held molecular diagnostic company; and prior to joining Asuragen, Dr. Carlson held increasingly senior positions at Abbott Laboratories over a 20-year period, including Vice President and General Manager of the Vysis molecular diagnostic business following its acquisition. In this role, he was wholly responsible for P&L; he tripled sales with a five-fold increase in profit; created and drove the commercialization strategy for UroVysion, one of the most successful oncology product introductions in the U.S. IVD market over the past 10 years. In previous positions, he was responsible for business development, licensing and strategic planning to establish new pharmaceutical and diagnostic platforms for the pediatric and women's health channels of the Ross Division of Abbott, and ran Abbott's global custom biopharmaceutical and specialty generics pharmaceutical business. Dr. Carlson graduated with Ph.D. in Botany and Plant Physiology from Southern Illinois University and was a post-doctoral research fellow at the Harbor Branch Oceanographic Research Institute, Ft. Pierce Florida.